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ABSTRACT: Background: Parkinson’s disease is an
intractable disorder with heterogeneous clinical presenta-
tion that may reﬂect different underlying pathogenic
mechanisms. Surrogate indicators of pathogenic pro-
cesses correlating with clinical measures may assist in
better patient stratiﬁcation. Mitochondrial function, which
is impaired in and central to PD pathogenesis, may rep-
resent one such surrogate indicator.
Methods: Mitochondrial function was assessed by respi-
rometry experiment in ﬁbroblasts derived from idiopathic
patients (n = 47) in normal conditions and in experimental
settings that do not permit glycolysis and therefore force
energy production through mitochondrial function.
Respiratory parameters and clinical measures were cor-
related with bivariate analysis. Machine-learning-based
classiﬁcation and regression trees were used to classify
patients on the basis of biochemical and clinical mea-
sures. The effects of mitochondrial respiration on
α-synuclein stress were assessed monitoring the protein
phosphorylation in permitting versus restrictive glycolysis
conditions.
Results: Bioenergetic properties in peripheral ﬁbroblasts
correlate with clinical measures in idiopathic patients,
and the correlation is stronger with predominantly non-
dopaminergic signs. Bioenergetic analysis under metabolic
stress, in which energy is produced solely by mitochondria,
shows that patients’ ﬁbroblasts can augment respiration,
therefore indicating that mitochondrial defects are reversible.
Forcing energy production through mitochondria, however,
favors α-synuclein stress in different cellular experimental
systems. Machine-learning-based classiﬁcation identiﬁed
different groups of patients in which increasing disease
severity parallels higher mitochondrial respiration.
Conclusion: The suppression of mitochondrial activity in
PD may be an adaptive strategy to cope with concomitant
pathogenic factors. Moreover, mitochondrial measures in
ﬁbroblasts are potential peripheral biomarkers to follow
disease progression. © 2019 The Authors.Movement Dis-
orders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder Society.
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Parkinson’s disease (PD) is a multisystem disorder char-
acterized by a broad spectrum of motor (stiffness, slow-
ness, tremor, gait and balance difﬁculties) and nonmotor
(cognitive, psychiatric, sleep, alertness, autonomic) distur-
bances. The latter may antedate the motor symptoms,
worsen as the disease advances, and predominate in caus-
ing disability during the later stages of the disease.1 PD
patients do not follow a uniform disease course, but
exhibit conspicuous differences in primary disease-related
and medication-induced complications as well as in the
rate of progression of the disease, reﬂecting the existence
of subtypes. In early PD, clinical characteristics are insufﬁ-
cient to identify subtypes.2 There is, however, consensus
that the age at onset of manifest disease is a major deter-
minant of progression, with a more progressive course
being associated with a higher age at onset.3
Better patient stratiﬁcation is essential in designing
clinical trials and may be achieved by integrating clini-
cal data with quantitative biomarkers to best reﬂect the
progression of the disease and its underlying biological
pathophysiology. Furthermore, these biomarkers may
have the potential to identify systems or persons at-risk
before overt expression of the disorder and will allow
earlier diagnosis and faster evaluation of clinical trials
outcomes. Ideal surrogate measures reﬂect processes in
a crucial causal pathway of the disease and correlate
with the true clinical outcome.4
Dysfunction in mitochondrial oxidative phosphoryla-
tion (OXPHOS) has been linked to PD by multiple sources
of converging evidence including genetic, toxicological,
and epidemiological studies.5-7 Mitochondrial complex I
damage induces parkinsonism in humans and models the
diseases in laboratory animals; moreover, mitochondrial
defects are detectable in peripheral cells of genetic and idi-
opathic PD cases.6,8-10 In addition, interventions targeting
mitochondria ameliorate pathology in multiple animal
models and improve respiration efﬁciency in patients’
ﬁbroblasts.11-13 Collectively, these elements indicate that
mitochondrial parameters might serve as an alternative
outcome to complement clinical measures.
We performed bioenergetic characterization in primary
ﬁbroblasts from a highly characterized cohort of 47 PD
patients to test the hypothesis that mitochondrial parame-
ters correlate with clinical features and may therefore be
informative of the clinical outcome. We applied statistical
models and machine-learning procedures to describe the
complex relationship between the different analyzed
parameters and achieved unbiased grouping of patients
on the basis of both clinical and laboratory measures. To
fully expose the mitochondrial defects, we performed bio-
chemical experiments under conditions of metabolic stress
where the function of glycolysis—which could compen-
sate and hide mitochondrial anomalies—is minimized.
Finally, we explored detrimental synergies between bioen-
ergetics and α-synuclein (α-syn) pathology in primary
ﬁbroblasts and differentiated neurons.
Materials and Methods
Patients
This cross-sectional study in PD patients is part of the
Proﬁling Parkinson’s Disease study. Patients were recruited
from the outpatient clinic for Movement Disorders of the
Department of Neurology of the Leiden University Medi-
cal Center (Leiden, the Netherlands) and nearby university
and regional hospitals. All participants fulﬁlled the
U.K. Parkinson’s Disease Society Brain Bank criteria for
idiopathic PD.14 Evaluations occurred between January
2013 and January 2016. Exclusion criteria were previous
or other disorders of the central nervous system, peripheral
nerve disorders inﬂuencing motor and/or autonomic func-
tioning, and psychiatric comorbidity not related to PD.
All patients except for 18 dopaminergic drug-naïve
patients were tested while on dopaminergic medication.
The severity of motor symptoms was quantiﬁed using the
Movement Disorder Society version of the Uniﬁed
Parkinson’s Disease Rating Scale (MDS-UPDRS) motor
examination (part III).15 In Addition, the Severity of
predominantly Non-dopaminergic Symptoms in PD
(SENS-PD) scale was administered, which is a composite
score comprising 3 items with 4 response options (0-3) from
each of the following six domains: postural instability and
gait difﬁculty, psychotic symptoms, excessive daytime sleep-
iness, autonomic dysfunction, cognitive impairment, and
depressive symptoms (total range 0-54).1 These 6 domains
represent a coherent complex of symptoms that largely do
not improve with dopaminergic medication that is already
present in the early disease stages and increases in severity
when the disease advances.16 Higher scores on both scales
reﬂect more severe impairment. Cognitive performance was
assessed using the Scales for Outcomes in Parkinson’s
Disease–Cognition (range 0-43), a valid and reliable instru-
ment examining the following domains: memory, attention,
executive functioning, and visuospatial functioning17; lower
scores reﬂect more severe impairment. A levodopa dose
equivalent of daily levodopa, dopamine agonists, and a
total levodopa dose equivalent was calculated according to
the formula developed by Tomlinson and colleagues.18
The study was approved by the medical ethics commit-
tee of the Leiden University Medical Center, and written
informed consent was obtained from all PD patients.
Fibroblasts Cultures
PD patients’ ﬁbroblasts were prepared isolated at
Leiden University Medical Center from skin biopsies
derived from the ventral side of the upper leg and cultured
under highly standardized conditions at 37C and 5%
Carbon dioxide (CO2) up to a maximum of 10 passages.
The number of passages was kept consistent within groups.
Fibroblasts were maintained in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) 10% Fetal Bovine Serum (FBS) and
1% penicillin-streptomycin (P4333, Sigma-Aldrich) until
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reaching conﬂuency. Prior to Seahorse analysis, ﬁbro-
blasts were rinsed with Phosphate-Buffered Saline (PBS)
and cultured with glucose (glucose 10 mM, 10% FBS
[F6178, Sigma-Aldrich], 2 mM glutamine, 5 mM Hepes,
and 1% penicillin-streptomycin (P4333, Sigma-Aldrich,
St. Louis, MI, USA) or galactose (galactose 10 mM, 10%
FBS, 2 mM glutamine, 5 mM Hepes, and 1% penicillin-
streptomycin) medium for 3 days. Fibroblasts from sex-
matched controls of comparable age were either obtained
from the Coriell biorepository (identiﬁcation codes
AG04659, AG05266, AG06283, AG07936, AG08152,
AG08268, AG08269, AG08543, AG09162, AG09271,
AG09879, AG12428, AG12951, AG13077, AG13348),
Coriell Institute for Medical Research (Camden, New
Jersey), or from the biorepository available in the
Department of Molecular Genetics of the ErasmusMedical
Center (MC), Rotterdam, The Netherlands.
Mitochondrial Respiration
and Glycolysis Determination
Bioenergetics proﬁles of human primary skin ﬁbroblasts
were generated in real time with a Seahorse XF24 Extra-
cellular Flux Analyzer (Agilent Technologies, Santa Clara,
California) as previously described.8,12 Fibroblasts were
seeded on a Seahorse XF-24 plate at a density of 6 × 104
cells per well and grown overnight in DMEM (10%
of FBS and 1% Pen-Strep) at 37C, 5% CO2. This
density ensures a proportional response to the uncoupler
Carbonyl cyanide-4-(triﬂuoromethoxy)phenylhydrazone
(FCCP) (Carbonyl cyanide 4-[triﬂuoromethoxy]phenyl-
hydrazone) with the cell number8,12 and resulted in
conﬂuent cultures in which cell replication was further
prevented by contact inhibition. In addition, no signiﬁcant
cell death occurred during the experiment, as indicated by
the uniform, dense layer of adherent cells (Supplementary
Fig. 1A). On the experimental day, the medium was chan-
ged to unbuffered DMEM (XF Assay Medium; Agilent
Technologies) supplemented with 5 mM glucose and
1 mM sodium pyruvate and incubated for 1 hour at
37C in the absence of CO2. Medium and reagent acidity
were adjusted to pH 7.4 on the day of the assay,
according to manufacturer’s procedure. After 4 baseline
measurements for the oxygen consumption ratio, the cells
were sequentially challenged with injections of mitochon-
drial toxins: 0.5 μM oligomycin (Adenosine triphosphate
(ATP) synthase inhibitor), 1 μM FCCP (mitochondrial
respiration uncoupler), 0.5 μM rotenone (complex I inhib-
itor), and 0.5 μM antimycin (complex III inhibitor).
A total of 3 Seahorse replicates were performed for
each ﬁbroblast line. In each replicate, we used 7 wells
for each line. In each run, 6 wells were always used for
a reference primary ﬁbroblast line with highly charac-
terized bioenergetics behavior. Because the behavior of
this cell line in the Seahorse run is reproducible and
ascertained, this additional precaution allows for
double checking the quality of the Seahorse run. Data
represent the mean of the different replicates.
Statistical Analysis
Statistical associations were determined using classi-
cal bivariate analysis: the Kruskall–Wallis test was used
for comparisons of quantitative against categorical vari-
ables, the chi-square test was used for comparisons of
categorical versus categorical variables, and the Spear-
man correlation coefﬁcient was used for the compari-
son of quantitative versus quantitative variables. The
signiﬁcance level was set at .05.
Individual mitochondrial parameters were compared
with the group means using 1-way ANOVA analysis of
variance and Dunnett’s test. A modiﬁed t test as
described in Crawford and Howell19 provided concep-
tually comparable results (data not shown).
Stratiﬁcation was achieved using applied classiﬁcation
and regression trees (CART).20 The rpart package21 in
R software22 was used to ﬁt data into CART, and the
function rpart was used with the analysis of variance.
All statistical analyses were performed in R version
3.3.2 (see also the Supporting Methods).
Results
Characterization of Mitochondrial Function
in Permitting Versus Nonpermitting
Glycolysis Conditions
Bioenergetics Analysis
PD presentation is highly heterogeneous and to be a real-
istic candidate as surrogate measure, mitochondrial func-
tion must consistently reﬂect such variability. We therefore
assessed the extent of heterogeneity in peripheral mitochon-
drial activity by performing extensive bioenergetics analysis
using a Seahorse Extracellular Flux Analyzer. We com-
pared individual data of patients’ ﬁbroblasts to the average
of a group of controls with comparable age and gender dis-
tribution (N = 21). To unravel the defects that are eventu-
ally masked in glycolysis-permitting conditions, we also
performed the experiments in conditions in which glucose
was replaced with galactose because the latter forces cells
to rely on mitochondria for ATP production. Of note, these
culturing conditions are lethal for ﬁbroblasts from patients
with mitochondrial pathologies.23 Surprisingly, however,
PD patients’ ﬁbroblasts perfectly survived in galactose
medium, and no cell death was observed (data not shown).
The results exposed signiﬁcant variability in both glu-
cose and galactose-cultured specimens (Fig. 1B,C). As
expected, forcing bioenergetics through oxidative metab-
olism (ie, galactose medium) unmasked anomalies, and
several lines that did not exhibit alterations in glucose
medium revealed differences in basal respiration when
cultured with galactose (Fig. 1D,E). However, no changes
were detected in reserve capacity (Fig. 1E). Galactose
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ability to amplify bioenergetics differences was also con-
ﬁrmed when a more general analysis was performed at
the group level, that is, pooled PD versus controls. Here,
the reserve capacity in the galactose medium was the only
signiﬁcant difference detected (Supplementary Fig. 1B-D).
Consistent with previous analyses on idiopathic PD8
or Parkin mutant ﬁbroblasts,24 we did not observe any dif-
ference in basal or stimulated extracellular acidiﬁcation
rate in both glucose- or galactose-culturing conditions
(Supplementary Fig. 1E).
Heterogeneity among PD specimens was also
observed in parameters related to mitochondrial func-
tion such as mitochondrial superoxide production and
ATP/ADP ratio (Fig. 1F).
PD Fibroblasts Can Augment Respiration
in Conditions Forcing Metabolism Through
Oxidative Phosphorylation
The adaptation of mitochondrial function to conditions
that force bioenergetics through oxidative metabolism (ie,
galactose medium) is reﬂected in the ratio between respi-
ration parameters obtained in galactose and glucose con-
ditions (galactose-to-glucose ratio).
In cells from healthy controls, the galactose medium
mostly augmented respiration (ie, galactose-to-glucose
ratio >1) and only 5 of 21 tested lines displayed
reduced reserve capacity (Fig. 2B).
The galactose medium also altered the mitochondrial
function in PD ﬁbroblasts, albeit the magnitude of
response was variable among the different lines (Fig. 2C).
The direction of the changes observed in the patient speci-
mens, however, was unexpected. In fact, given the mito-
chondrial defects intrinsic to PD, which are observed also
peripherally, one would predict an inability to augment
respiration and even lethality—that is, the opposite out-
come than in control cells—as reported for typical mito-
chondrial disorders.23 However, basal respiration, reserve
capacity, and rotenone-sensitive respiration signiﬁcantly
increased in several PD ﬁbroblast lines, whereas only 1 of
the analyzed PD specimens displayed a reduction, exclu-
sively in reserve capacity (Fig. 2E). This evidence indicates
that, rather than being irreversibly compromised, mito-
chondrial dysfunction in the ﬁbroblasts of PD patients
can be restored under certain metabolic conditions.
Overall, these results indicate that analysis under
metabolic challenge may amplify PD distinctive bio-
chemical features and also demonstrate heterogeneity in
peripheral PD specimens. The next logical question is
whether variability in these parameters reﬂects and cor-
relates with clinical manifestations.
Correlation Between Laboratory and Clinical
Measures
We next examined whether the variability observed in
respiration parameters might reﬂect clinical characteristics.
No signiﬁcant correlations (rs) were found between
respirometry parameters and age, age at onset, disease
duration, or levodopa equivalent doses; in addition, the
severity of motor symptoms did not correlate with any
of the laboratory parameters (Fig. 3A). However, the
SENS-PD scores correlated with glucose reserve capac-
ity (rs = 0.342, P = .026), whereas the Scales for Out-
comes in Parkinson’s Disease–Cognition score
displayed signiﬁcant correlations with reserve capacity
in the glucose medium (rs = −0.370, P = .017) and
rotenone-sensitive respiration (rs = −0.320, P = .041) in
the glucose medium (Fig. 4A,B). In addition, a correla-
tion was found between the MDS UPDRS III and both
mitochondrial superoxide and ATP/ADP levels deter-
mined in galactose (rs = 0.344, P = .026 and rs =
−0.337, P = .0292, respectively); these correlation coef-
ﬁcients indicate that the higher symptom severity is
associated with higher superoxide production and
lower ATP/ADP levels. Association was not found
when the cells were cultured in the glucose medium,
further conﬁrming the higher ability of galactose condi-
tions to reveal PD-related differences.
Unbiased Grouping of Patients on the Basis
of Laboratory and Clinical Measures
The heterogeneity in clinical presentation, the disper-
sion we observed in mitochondrial physiology, and
their correlation lend support to the hypothesis that
there may be subgroups of different mitochondrial phe-
notypes correlating with the symptomatology in the
general population of idiopathic PD patients. To test
this possibility, we used machine-learning methodology
and recursive partitioning to build a CART,25 which
have been successfully used in applications such as clin-
ical subtypes classiﬁcation26 and neuroimaging data
analysis to predict Alzheimer’s disease.27
All available parameters—that is, demographic vari-
ables (ie, age, age at onset, duration of the disease, and
gender), the equivalent of levodopa medication, respi-
rometry, and acidiﬁcation parameters—were used in
the CART process as input variables to predict either
the SENS-PD or the MDS-UPDRS III (ie, response vari-
ables). Intrinsic to CART modeling is a selection step
that eliminates in an unbiased fashion redundancy
among the input variables to identify the most signiﬁ-
cant parameters.
When the CART analysis was applied using SENS-
PD as a response variable, 3 rules—nodes 1, 2, and 3—
grouped the cases in 4 classes (Fig. 3D). The ﬁrst rule,
node 1, identiﬁes disease duration as a classifying vari-
able and identiﬁes a class of patients (class 4) with dis-
ease duration longer than 9.45 years presenting with
the most severe symptoms. The second and third
rules—nodes 2 and 3—respectively identify basal respi-
ration in galactose and reserve capacity in a glucose
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FIG. 1. (A) Clinical description of patients and controls included in this research. (B, C) Analysis of individual bioenergetics data highlights high variability in
reserve capacity and in rotenone sensitive respiration in both glucose (B) and galactose (C) medium conditions. (D) Heat map plotting statistical signiﬁcance
values of the differences between individual patients’ respiration data and the mean of healthy controls. Signiﬁcance was determined using one-way analysis
of variance and Dunnett’s test. (E) Bar graph showing the number of patients with statistically signiﬁcant difference in respiratory parameters. (F) Bar graphs
and heat map illustrating variability in mitochondrial superoxide (Mitosox) production and ATP/ADP ratio in individual PD specimens when compared with the
average of the control group (green = downregulation, red = upregulation; P < .05). CTRL, controls; ID, identiﬁcation; f, female; m, male; OCR, oxygen con-
sumption rate ; SCOPA-COG, Scales for Outcomes in Parkinson’s Disease–Cognition.
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medium as classifying variables and divide patients with
disease duration shorter than 9.45 years into 3 further
classes. Class 1 is deﬁned by lower galactose basal res-
piration (<175.5 pmol/min−1) and lower glucose reserve
capacity (<112.5 pmol/min−1) and includes patients
with the least severe clinical presentation. Class
2 includes patients with lower galactose basal respira-
tion, but higher glucose reserve capacity, and in class
3 both respiration parameters are higher. Presentation
in these 2 classes is more severe than in class 1, with
class 3 encompassing patients with worse symptoms.
Overall, these data indicate that in patients with shorter
FIG. 2. Analysis of the galactose-to-glucose respiration ratio as an index of mitochondria alterations induced by conditions that do not permit glycoly-
sis. (A) Replacing glucose with galactose alters respiration parameters in control cells. The heat map illustrates statistical signiﬁcance values obtained
testing the hypothesis that in control specimens the galactose-to-glucose respiration ratios are different than one, which would indicate altered respira-
tion in non-permitting versus permitting glycolysis conditions. (B) Heat map illustrating the direction of the changes in the galactose-to-glucose ratios;
red indicates a ratio higher than one, i.e. upregulation of respiration in galactose. The vast majority of control lines potentiates respiration when bioener-
getics is forced through OXPHOS. (C) Representative Seahorse trace and histograms of respiratory parameters of individual bioenergetics data
expressed as galactose over glucose ratio. (D) Heat map displaying statistical signiﬁcance values obtained testing the hypothesis that in PD specimens
the galactose-to-glucose respiration ratios are different than one. (E) Heat map illustrating the direction of the changes in the galactose-to-glucose
ratios; red indicates a ratio higher than one, i.e. upregulation of respiration in galactose. The vast majority of PD lines augments respiration when bioen-
ergetics is forced through OXPHOS. Signiﬁcance was determined using one-way analysis of variance and Dunnett’s tests. CTRL, controls; ID, identiﬁ-
cation; OCR, oxygen consumption rate.
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disease duration (ie, less than 9.45 years) higher respi-
ration is associated with increasing symptom severity.
When the MDS-UPDRS was used as response variable,
CART analysis returned only 2 rules (node 1, rotenone-
sensitive respiration in galactose; node 2, rotenone-sensitive
respiration in glucose), dividing the patients in 3 classes
(Fig. 3E). Also, in this case higher values in respiration
parameters are associatedwithmore severe symptoms.
Increased Mitochondrial Function Promotes α-Syn
Stress In Vitro
Taken together, our combined biochemical and clinical
data indicate that mitochondrial function is suppressed in
PD patients’ ﬁbroblasts and—given that lower respiration
correlates with less severe symptoms—this alteration may
reﬂect a protective adaptation to counterbalance PD patho-
genesis. As a corollary, highmitochondrial activity may syn-
ergize with other pathogenic factors to elicit deterioration.
Given that α-syn aggregation and stress are hallmarks of
PD, we hypothesized that forcingmitochondrial activity in a
galactose medium could favor synucleinopathy. Investigat-
ing these aspects in ﬁbroblasts, however, poses critical issues
because α-syn expression is extremely low in this cell type.28
We therefore took advantage of lentiviral technology to
engineer ﬁbroblasts to express Green Fluorescent Protein
(GFP)-tagged human α-syn in 3 control lines (AG08268,
FIG. 3. Correlation between raw respiration data and clinical measures. (A) Multivariate analysis of variance showing Spearman’s correlation coefﬁ-
cients between laboratory and clinical measures and related signiﬁcance. (B) Graphs of clinical and raw laboratory variables displaying statistically sig-
niﬁcant correlations. (C) Linear regression with interactions and analysis of variance indicates that correlation between the clinical and laboratory
measures is independent from gender, age, age at onset, duration of the disease, and medication. (D) Grouping of patients using unbiased classiﬁca-
tion and regression tree analysis using the SENS-PD as a response variable. (E) Classiﬁcation and regression trees analysis using the MDS-UPDRS
score as response variable. ECAR, extracellular acidiﬁcation rate; SCOPA-COG, Scales for Outcomes in Parkinson’s Disease–Cognition.
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AG08543, andAG13077) and 3 PD lines able to upregulate
mitochondrial function in galactose (3020, 3039, and
3086). We evaluated protein stress by measuring the num-
ber of foci of phosphorylated α-syn (p-syn), which is the
principal modiﬁed species of a-syn within PD pathological
inclusions29; intracellular foci therefore reﬂect early forms of
aggregation.
In control cells, the galactose medium conditions cau-
sed a signiﬁcant increase in the number of p-syn foci—
which were quantiﬁed by an unbiased semiautomated
procedure—therefore indicating that increased mito-
chondrial function may indeed favor synucleinopathy.
In PD ﬁbroblasts, p-syn levels were also elevated in
glucose conditions and did not show any further
increase in galactose (Fig. 4A,B). These effects were not
caused by different levels of α-syn-GFP because the
exogenous protein was expressed at comparable levels
in the control and PD specimens (Fig. 4C, green signal).
Of note, the observed effect cannot be attributed—at
least unambiguously—to increased production of Reactive
Oxygen Species (ROS) because 2 (3039 and 3086) of the
3 tested PD lines did not exhibit a signiﬁcant increase in
mitochondrial superoxide production (Fig. 1F).
To determine whether forcing bioenergetics metabolism
through mitochondrial function also aggravates endoge-
nous α-syn stress in neuronal cells, we investigated
FIG. 4. Increased mitochondrial function in galactose medium favors α-syn stress. (A) Representative laser scanning confocal microscopy imaging
showing GFP-tagged α-syn (green) and p-syn (red) levels. In healthy controls (N = 3), galactose signiﬁcantly increases the number of intracellular p-syn
foci (arrowheads) pointing to α-syn stress. In PD cells (N = 3), p-syn levels are elevated also in glucose conditions and do not increase in galactose
medium. (B) Quantiﬁcation of intracellular p-syn foci. (C) Quantiﬁcation of α-syn GFP levels indicating comparable levels in control and PD specimens.
(E) Representative laser scanning confocal microscopy imaging of differentiated SH-SY5Y cells showing endogenous α-syn (green) and p-syn (red)
levels in glucose- or galactose-culturing conditions. (F) Quantiﬁcation of intracellular p-syn foci showing increased α-syn stress in galactose medium.
(G) Quantiﬁcation of endogenous α-syn shows no differences between the 2 culturing conditions. **P < .0021, Kruskal–Wallis nonparametric test. Scale
bar = 10 μm. α-syn, α-synuclein; A.U., Arbitrary Unit; n.s., not signiﬁcant; p-syn, phosphorylated α-synuclein.
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differentiated SH-SY5Y cells. This dopaminergic cell line
expresses detectable levels of endogenous α-syn, which do
not differ between glucose- or galactose-culturing condi-
tions (Fig 4D,F). However, cells grown in the galactose
medium exhibited signiﬁcantly increased levels of p-syn
(Fig. 4D,E), conﬁrming the data obtained in over-
expressing cells. Taken together, these ﬁndings indicate
that the complex genetic background of idiopathic
patients promotes per se α-syn stress and that suppression
of mitochondrial function to mitigate synucleinopathy is
ineffective in PD cells.
Discussion
The data presented in this study are completely consis-
tent and conﬁrm previous observations from others and
our laboratories showing impairment in mitochondrial
function in PD.6,8 However, in this study we report the
unexpected and surprising ﬁnding that mitochondrial
function in PD patients peripheral ﬁbroblasts can be
potentiated in conditions forcing OXPHOS, that is, in a
galactose medium, which were used to reveal alterations
in genetically stratiﬁed PD ﬁbroblasts also in previous
studies.30-32 This evidence provides an alternative perspec-
tive on the current view of mitochondria in PD and sug-
gests that, rather than being irreversibly damaged,
mitochondrial function is suppressed. A possible hypothe-
sis to explain this observation is that in PD mitochondria
may suffer from intrinsic anomalies resulting in harmful
consequences if the organelles function at normal levels
and/or that mitochondrial activity may promote other
PD-related pathogenic processes. Consistent with the lat-
ter hypothesis, the galactose medium induced an increase
in α-syn stress—indicated by increased p-syn levels—in
the Green Fluorescent Protein-synuclein (GFP-syn)
expressing ﬁbroblasts from healthy subjects. Experiments
in engineered ﬁbroblasts and differentiated SHSY-5Y cells
also revealed that α-syn stress occurs at high levels in PD
cells when grown in glucose and does not increase in
galactose, therefore indicating that the complex genetic
background of idiopathic PD patients promotes α-syn
stress per se. Additional studies will be necessary to
unravel possible connections between α-syn aggregation
and mitochondrial respiration and their potential role in
PD pathogenesis.
A protective role for the suppression of mitochondrial
function is consistent with recent hypotheses suggesting
that neurodegeneration in Alzheimer’s disease is caused
by metabolic alterations and that dysfunctional neurons
upregulate mitochondrial respiration according to an
inverse-Warburg effect pathogenic paradigm.33,34 We
have recently demonstrated that mild inhibition of com-
plex I caused by nitrite-mediated complex I S-nitrosation
is protective in multiple models of PD and improves bio-
energetic efﬁciency in the ﬁbroblasts of PD patients, but
not in matched controls.12 A protective role for mito-
chondrial suppression is further substantiated by other
independent studies that have shown that the reversible
complex I inhibitor Mitochondrial division inhibitor 1
(Mdivi-1)35 is protective in PD animal models11,13 and
that proteolytic degradation of complex I attenuates
ROS production in damaged, depolarized mitochon-
dria.36 In addition, it has been shown that ﬁbroblasts
from patients harboring mutations in the PD-associated
gene ATPase cation transporting 13A2 (ATP13A2) dis-
play higher, rather than lower, mitochondrial oxygen
consumption, which is in turn associated with multiple
mitochondrial anomalies.37 Together with the evidence
presented in this study, these data suggest that—at least
in some subtypes of PD—mitochondrial function could
be an amenable target for disease modiﬁcation.
Two mitochondrial variables—reserve capacity and
rotenone-sensitive (ie, complex I driven) respiration—
correlate with the SENS-PD scale. These results conﬁrm
the pivotal role of complex I in PD pathobiology and are
consistent with previous studies indicating that reserve
capacity is very sensitive to stress and therefore particu-
larly suited to detect systemic physiological anoma-
lies.38,39 The SENS-PD scale addresses clinical features
that mostly do not improve on dopaminergic treatment.16
It is likely that these predominantly nondopaminergic
items more accurately reﬂect the severity and progression
of the underlying disease pathobiology.1
We used CART analysis20—a machine-learning meth-
odology using recursive partitioning—to classify patients
on the basis of clinical and bioenergetic measures. CART
(which has been already used to analyze biomedical
problems40 and has been used to stratify patients26) has
several advantages over traditional approaches such as
generalized linear models (eg, linear regression, logistic
regression, among others). First, the method is nonpara-
metric and thus does not assume any distribution model
for the dependent variable. Second, it can handle a large
set of explanatory variables, and it automatically selects
the most important variables to be used in the ﬁnal
model. Compared to classical regression methods where
variable selection is an open problem with no deﬁnitive
answer,41 CART analysis is data driven and identiﬁes
interactions objectively, in an unbiased manner, and
does not require any input from the researcher.
Not surprisingly, the highest hierarchical discriminant
of clinical phenotypes is disease duration, with longer
durations associated with more severe clinical presenta-
tion. The other classifying variables selected by CART
among the multitude of demographic, clinical, and bio-
energetic parameters are related to mitochondrial func-
tion, and the analysis indicates that patients falling in
classes with higher respiration present with increased
severity of symptoms. Of note, 2 independent statistical
methods—that is, multivariate analysis of variance and
CART analysis—identify mitochondrial respiration as a
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predictor of clinical symptoms. These data substantiate
the relevance of mitochondrial biology in PD pathogen-
esis and further support the hypothesis that suppression
of mitochondrial function during PD pathogenesis
might represent a protective adaptive response.
Using the SENS-PD scale as response variable led to
better separation of patients with shorter disease dura-
tion and milder symptoms, therefore conﬁrming the
concept that signs outside the dopaminergic domain—
which are less sensitive to dopaminergic medications,
may manifest at earlier stages, and are enriched in the
SENS-PD scale—can be highly informative for PD
phenotyping and to monitor the disease progression.1
Here we propose a novel approach; its methodologies,
algorithms, and the consequent results must be repli-
cated in independent experiments. More studies and
subsequent publications obtained in possibly larger
cohorts also backing up the Seahorse approach with
other methodologies will be necessary to conclusively
conﬁrm a possible association between peripheral mito-
chondrial function and clinical symptoms and the clini-
cal and scientiﬁc relevance.
In summary, our study reveals new aspects of mito-
chondrial biology in PD, indicates a connection
between clinical and laboratory measures, and may lay
a foundation for better stratiﬁcation of patients.
References
1. van der Heeden JF, Marinus J, Martinez-Martin P, van Hilten JJ.
Importance of nondopaminergic features in evaluating disease sever-
ity of Parkinson disease. Neurology 2014;82(5):412-418.
2. Marras C, Lang A. Parkinson’s disease subtypes: lost in translation?
J Neurol Neurosurg Psychiatry 2013;84(4):409-415.
3. van Rooden SM, Verbaan D, Stijnen T, Marinus J, van Hilten JJ.
The inﬂuence of age and approaching death on the course of non-
dopaminergic symptoms in Parkinson’s disease. Parkinsonism Relat
Disord 2016;24:113-118.
4. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are
we being misled? Ann Intern Med 1996;125(7):605-613.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV,
Greenamyre JT. Chronic systemic pesticide exposure reproduces fea-
tures of Parkinson’s disease. Nat Neurosci 2000;3(11100151):1301-
1306.
6. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB,
Marsden CD. Mitochondrial complex I deﬁciency in Parkinson’s dis-
ease. Lancet 1989;1(8649):1269.
7. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and
Parkinson’s disease. Environ Health Perspect 2011;119(6):866-872.
8. Ambrosi G, Ghezzi C, Sepe S, et al. Bioenergetic and proteolytic
defects in ﬁbroblasts from patients with sporadic Parkinson’s dis-
ease. Biochim Biophys Acta 2014;1842(9):1385-1394.
9. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial
impairment in patients with Parkinson disease with the G2019S
mutation in LRRK2. Neurology 2010;75(22):2017-2020.
10. Piccoli C, Sardanelli A, Scrima R, et al. Mitochondrial respiratory
dysfunction in familiar parkinsonism associated with PINK1 muta-
tion. Neurochem Res 2008;33(12):2565-2574.
11. Bido S, Soria FN, Fan RZ, Bezard E, Tieu K. Mitochondrial division
inhibitor-1 is neuroprotective in the A53T-alpha-synuclein rat model
of Parkinson’s disease. Sci Rep 2017;7(1):7495.
12. Milanese C, Tapias V, Gabriels S, et al. Mitochondrial complex I
reversible S-nitrosation improves bioenergetics and is protective in
Parkinson’s disease. Antioxid Redox Signal 2018;28(1):44-61.
13. Rappold PM, Cui M, Grima JC, et al. Drp1 inhibition attenuates
neurotoxicity and dopamine release deﬁcits in vivo. Nat Commun
2014;5:5244.
14. Gibb WR, Lees AJ. The relevance of the Lewy body to the patho-
genesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psy-
chiatry 1988;51(6):745-752.
15. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder
Society-sponsored revision of the Uniﬁed Parkinson’s Disease Rating
Scale (MDS-UPDRS): scale presentation and clinimetric testing
results. Mov Disord 2008;23(15):2129-2170.
16. van der Heeden JF, Marinus J, Martinez-Martin P, van Hilten JJ.
Evaluation of severity of predominantly non-dopaminergic symp-
toms in Parkinson’s disease: the SENS-PD scale. Parkinsonism Relat
Disord 2016;25:39-44.
17. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in
Parkinson’s disease. Neurology 2003;61(9):1222-1228.
18. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Sys-
tematic review of levodopa dose equivalency reporting in
Parkinson’s disease. Mov Disord 2010;25(15):2649-2653.
19. Crawford JR, Howell DC. Comparing an individual’s test score
against norms derived from small samples. Clin Neuropsychol 1998;
12(4):482-486.
20. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classiﬁcation and
Regression Trees. Monterey, CA: Wadsworth; 1984.
21. Therneau T, Atkinson B, Ripley B, Ripley MB. Package “rpart.”
uk/web/packages/rpart/rpart.pdf. Accessed April 20, 2016.
22. R Core Team. R: A Language and Environment for Statistical Com-
puting. R Foundation for Statistical Computing, Vienna. https://
www.R-project.org. Accessed April 20, 2016.
23. Robinson BH, Petrova-Benedict R, Buncic JR, Wallace DC. Non-
viability of cells with oxidative defects in galactose medium: a
screening test for affected patient ﬁbroblasts. Biochem Med Metab
Biol 1992;48(2):122-126.
24. Zanellati MC, Monti V, Barzaghi C, et al. Mitochondrial dysfunc-
tion in Parkinson disease: evidence in mutant PARK2 ﬁbroblasts.
Front Genet 2015;6:78.
25. Breiman L. Random forests. Mach Learn 2001;45(1):5-32.
26. Saito S, Ohno K, Sese J, Sugawara K, Sakuraba H. Prediction of the
clinical phenotype of Fabry disease based on protein sequential and
structural information. J Hum Genet 2010;55(3):175.
27. Sarica A, Cerasa A, Quattrone A. Random Forest algorithm for the
classiﬁcation of neuroimaging data in Alzheimer’s disease: a system-
atic review. Front Aging Neurosci 2017;9(329).
28. Auburger G, Klinkenberg M, Drost J, et al. Primary skin ﬁbroblasts
as a model of Parkinson’s disease. Mol Neurobiol 2012;46(1):
20-27.
29. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of
Ser-129 is the dominant pathological modiﬁcation of alpha-
synuclein in familial and sporadic Lewy body disease. J Biol Chem
2006;281(40):29739-29752.
30. Mortiboys H, Thomas KJ, Koopman WJ, et al. Mitochondrial func-
tion and morphology are impaired in parkin-mutant ﬁbroblasts.
Ann Neurol 2008;64(5):555-565.
31. Papkovskaia TD, Chau KY, Inesta-Vaquera F, et al. G2019S
leucine-rich repeat kinase 2 causes uncoupling protein-mediated
mitochondrial depolarization. Hum Mol Genet 2012;21(19):4201-
4213.
32. Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C,
Bandmann O. UDCA exerts beneﬁcial effect on mitochondrial dys-
function in LRRK2(G2019S) carriers and in vivo. Neurology 2015;
85(10):846-852.
33. Demetrius LA, Magistretti PJ, Pellerin L. Alzheimer’s disease: the
amyloid hypothesis and the Inverse Warburg effect. Front Physiol
2014;5:522.
Movement Disorders, Vol. 34, No. 8, 2019 1201
M I T O C H O N D R I A A N D C L I N I C A L M E A S U R E S I N P D
34. Demetrius LA, Simon DK. An inverse-Warburg effect and the origin
of Alzheimer’s disease. Biogerontology 2012;13(6):583-594.
35. Bordt EA, Clerc P, Roelofs BA, et al. The putative Drp1 inhibitor
mdivi-1 is a reversible mitochondrial complex I inhibitor that modu-
lates reactive oxygen species. Dev Cell 2017;40(6):583-594 e586.
36. Pryde KR, Taanman JW, Schapira AH. A LON-ClpP proteolytic
axis degrades complex I to extinguish ROS production in
depolarized mitochondria. Cell Rep 2016;17(10):2522-2531.
37. Grunewald A, Arns B, Seibler P, et al. ATP13A2 mutations impair
mitochondrial function in ﬁbroblasts from patients with Kufor-
Rakeb syndrome. Neurobiol Aging 2012;33(8):1843 e1841-1847.
38. Hill BG, Dranka BP, Zou L, Chatham JC, Darley-Usmar VM. Impor-
tance of the bioenergetic reserve capacity in response to cardiomyocyte
stress induced by 4-hydroxynonenal. Biochem J 2009;424(1):99-107.
39. Kramer PA, Ravi S, Chacko B, Johnson MS, Darley-Usmar VM. A
review of the mitochondrial and glycolytic metabolism in human
platelets and leukocytes: implications for their use as bioenergetic
biomarkers. Redox Biol 2014;2:206-210.
40. Xiang C, Minghui W, Heping Z. The use of classiﬁcation trees for
bioinformatics. Wiley Interdiscip Rev Data Min Knowl Discov
2011;1(1):55-63.
41. Harrell FE. Regression Modeling Strategies, With Applications to Lin-
ear Models, Survival Analysis and Logistic Regression. New York:
Springer; 2001.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
1202 Movement Disorders, Vol. 34, No. 8, 2019
M I L A N E S E E T A L
